Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?

Multiple Sclerosis

Volumn 15, Issue 9, 2009, Pages 1043-1047

  Bonzano, L ^a   Roccatagliata, L ^a   Mancardi, G L ^a   Sormani, Maria Pia ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Clinical trial; Gadolinium; Magnetic resonance; Meta analysis; Multiple sclerosis; Randomized controlled trial; Relapsing remitting multiple sclerosis

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; GADOLINIUM; PLACEBO; ROQUINIMEX; TERIFLUNOMIDE;

ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; HUMAN; META ANALYSIS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION WEIGHTED IMAGING; RANDOMIZED CONTROLLED TRIAL;

DRUG MONITORING; GADOLINIUM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS;

EID: 69149096656     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509106610     Document Type: Article

References (17)

1. Paty, DW. Trial measures in multiple sclerosis: The use of magnetic resonance imaging in the evaluation of clinical trials. Neurology 1988; 38(Suppl. 2): 82-83.
2. Rovaris, M, Filippi, M. Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis. Curr Opin Neurol 1999; 12: 337-344.
3. Miller, DH, Barkhof, F, Nauta, JJ. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993; 116: 1077-1094.
4. Miller, DH, Albert, PS, Barkhof, F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996; 39: 6-16.
5. Sormani, MP, Bonzano, L, Roccatagliata, L, Cutter, GR, Mancardi, GL, Bruzzi, P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach. Ann Neurol 2009; 65: 268-275.
6. Sormani, MP, Bruzzi, P, Miller, DH, Gasperini, C, Barkhof, F, Filippi, M. Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: Implications for clinical trials. J Neurol Sci 1999; 163: 74-80.
7. Andersen, O, Lycke, J, Tollesson, PO, et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 1996; 47: 895-900.
8. Comi, G, Filippi, M, Wolinsky, JS. European/Canadian multicenter, double-blind, randomized, placebocontrolled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290-297.
9. Kappos, L, Antel, J, Comi, G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-1140.
10. OConnor, PW, Li, D, Freedman, MS, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66: 894-900.
11. Panitch, H, Goodin, DS, Francis, G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The evidence trial. Neurology 2002; 59: 1496-1506.
12. Kappos, L, Gold, R, Miller, DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, doubleblind, placebo-controlled phase IIb study. Lancet 2008; 372: 1463-1472.
13. Filippi, M, Campi, A, Martinelli, V, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1995; 59: 540-544.
14. Rovaris, M, Barkhof, F, Bastianello, S, et al. Multiple sclerosis: interobserver agreement in reporting active lesions on serial brain MRI using conventional spin echo, fast spin echo, fast fluid-attenuated inversion recovery and post-contrast T1-weighted images. J Neurol 1999; 246: 920-925.
15. Moraal, B, Meier, DS, Poppe, PA, et al. Subtraction MR images in a multiple sclerosis multicenter clinical trial setting. Radiology 2009; 250: 506-514.
16. Martin, DR. Nephrogenic system fibrosis: A radiologist's practical perspective. Eur J Radiol 2008; 66: 220-224.
17. Miller, DH, Rudge, P, Johnson, G, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988; 111: 927-939.